New Alpha-Particle drug targets Hard-to-Treat thyroid cancer
NCT ID NCT07287748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new radioactive drug called Af-001 in people with advanced differentiated thyroid cancer that cannot be removed by surgery or has spread. The study has two parts: first, to find the safest dose, and second, to see if multiple doses can shrink tumors. About 38 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Af-001 (a radioactive drug that emits alpha particles)
What this could lead to
If successful, this could provide a new treatment option for people with advanced thyroid cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 38 participants, so safety and effectiveness are not yet proven. The radioactive drug may cause serious side effects like low blood counts or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Japan